UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

Journal of clinical oncology, 2012-11, Vol.30 (33), p.4117-4123

2012

Link zum Volltext

Verfügbarkeit prüfen

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma

Hematology/oncology clinics of North America, 2016-12, Vol.30 (6), p.1277-1291

2016

Link zum Volltext

Verfügbarkeit prüfen

Radiation and Dose‐densification of R‐CHOP in Aggressive B‐cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

HemaSphere, 2023-07, Vol.7 (7), p.e904-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to A. Korfel et al

Journal of clinical oncology, 2016-05, Vol.34 (15), p.1831-1832

2016

Link zum Volltext

Verfügbarkeit prüfen

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Journal of clinical oncology, 2016-09, Vol.34 (26), p.3150-3156

2016

Link zum Volltext

Verfügbarkeit prüfen

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

The Lancet (British edition), 2019-12, Vol.394 (10216), p.2271-2281

2019

Link zum Volltext

Verfügbarkeit prüfen

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial

Leukemia, 2024-05, Vol.38 (5), p.1099-1106

2024

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood, 2021-05, Vol.137 (19), p.2646-2656

2021

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease

Bone marrow transplantation (Basingstoke), 2019-06, Vol.54 (6), p.877-884

2019

Link zum Volltext

Verfügbarkeit prüfen

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When?

Hematology/oncology clinics of North America, 2016-12, Vol.30 (6), p.1277-1291

2016

Link zum Volltext

Verfügbarkeit prüfen

Standard chemotherapy followed by allogeneic or autologous transplantation: The role of allogeneic transplantation in the AATT study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7534-7534

2022

Link zum Volltext

Verfügbarkeit prüfen

Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE‐R‐MegaCHOEP trial

British journal of haematology, 2019-03, Vol.184 (5), p.760-768

2019

Link zum Volltext

Verfügbarkeit prüfen

Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE ‐R‐Mega CHOEP trial

British journal of haematology, 2019-03, Vol.184 (5), p.760-768

2019

Link zum Volltext

Verfügbarkeit prüfen

Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8041-8041

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood, 2021-05 (2020008825)

2021

Link zum Volltext

Verfügbarkeit prüfen

First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7503-7503

2019

Link zum Volltext

Verfügbarkeit prüfen

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma

Cancer, 2011-05, Vol.117 (9), p.1901-1910

2011

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Blood, 2015-12, Vol.126 (23), p.474-474

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)
Tagungsberichte
(1)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Hematology
(14)
Humans
(12)
Female
(11)
Male
(11)
Middle Aged
(11)
Adult
(10)
Oncology
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Aged
(6)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(6)
Treatment Outcome
(6)
Adolescent
(5)
B-Cell Lymphoma
(5)
Cyclophosphamide - Administration & Dosage
(5)
Doxorubicin - Administration & Dosage
(5)
Lymphoma
(5)
Prognosis
(5)
Rituximab
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma

Radiation and Dose‐densification of R‐CHOP in Aggressive B‐cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

Radiation and Dose‐densification of R‐CHOP in Primary Mediastinal B‐cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial

Reply to A. Korfel et al

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When?

Standard chemotherapy followed by allogeneic or autologous transplantation: The role of allogeneic transplantation in the AATT study

Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE‐R‐MegaCHOEP trial

Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE ‐R‐Mega CHOEP trial

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA)

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Suchergebnisse filtern